BY SAVING SIGHT
A Bio-Inspired Therapeutic Platform
That Offers A bright future
for patients Suffering From
blinding ocular diseases
A PARADIGM CHANGE IN THE TREATMENT
OF OCULAR DISEASES
A Bio-Inspired Therapeutic Platform That Offers A bright future
for patients Suffering From blinding ocular diseases
We are a late clinical-stage company dedicated to developing disruptive bio-inspired medical solutions for the treatment and cure of autoimmune and inflammatory ocular diseases. Benefiting from the combined knowledge and experience of some of the world’s foremost experts on inflammatory ocular diseases, and after successful initial clinical trials, we believe our molecule-derived breakthrough approach has the potential to effectively control a range of autoimmune and inflammatory ocular diseases. Read more >>
Science & Technology
TRS, the Tarsier breakthrough platform technology, approaches inflammatory diseases from within the immune system. Tarsier™ Pharma implements a patented, proprietary new molecule which was developed to ‘re-engineer’ the immune system.
Ocular inflammatory diseases impose a significant medical and economic burden on society, affecting hundreds of millions people worldwide and posing severe risks of vision loss and blindness. Our pipeline includes two administration routes of eye drops and intravitreal injections.
Our first indication will be non-infectious anterior uveitis, a serious recurrent inflammation of the middle layer of the eye, the uvea. Active uveitis requires immediate treatment to maintain sight. Uveitis is responsible for 10-15% of all cases of blindness, with approximately 30,000 new cases diagnosed annually.
First Patient Randomized In TRS4VISION Phase-III Clinical Trial In Patients With Active Non-Infectious Anterior Uveitis Including Patients With